# UPL share price today (UPL Ltd, NSE: UPL)

> UPL share price today: ₹529.00 at the NSE close on 4 November 2026, down 29.3% in a year. UPL (NSE: UPL) is worth ₹44,673 crore, trades at a P/E of 22.6 and has closed between ₹488.45 and ₹804.65 over the past 52 weeks. > UPL Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. UPL · Pesticides/Agrochemicals · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/upl-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹529.00 (−29.3% in a year)
- P/E: 22.6× (higher than 53% of the last 11 years)
- Revenue (Jun 2026): ₹10,181 Cr (+10.5% on a year ago)
- Profit (Jun 2026): −₹73.0 Cr
- Operating margin: 13.0% (−2.0 points on a year ago)
- ROCE: 10%, FY26

The main question: yearly earnings per share moved +114.5% while the share price moved −29.3%. ## What is the UPL share price today? UPL Ltd's share price was ₹529.00 at the close on 4 November 2026. It has been falling for 33 weeks. That is 12.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹488 and ₹805, and at that close it sat 13% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running. Over the last 11 years the share price moved +89% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at UPL this quarter? Two changes stood out: indian funds and insurers (DIIs) cut their stake for 8 quarters in a row and revenue up on a year earlier for 9 quarters in a row. 1. Indian funds and insurers (DIIs) cut their stake for 8 quarters in a row From 18.9% to 14.3% of the company by the September 2026 quarter. 2. Revenue up on a year earlier for 9 quarters in a row In the June 2026 quarter revenue was ₹10,181 crore, +10.5% on a year earlier. Why: Revenue rose because the seeds and specialty chemicals businesses had strong starts to the year and helped group sales. Next results: check whether late buying by crop protection customers turns into reported sales. From the earnings call on 3 Aug 2026. ## What are UPL's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), UPL reported revenue of ₹10,181 crore, up 10.5% from ₹9,216 crore a year earlier, and a loss of ₹73.0 crore. ### UPL results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹10,181 crore | ₹9,216 crore | +10.5% |
| Profit | loss of ₹73.0 crore | loss of ₹176 crore | n/a |
| Earnings per share | ₹0.12 | ₹−1.04 | n/a |
| Operating margin | 13.0% | 15.0% | −2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). UPL's management discussed these results on a call held on 3 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the UPL share price history? UPL closed at ₹529.00 on 4 November 2026, down 29.3% from ₹747.95 a year earlier (7 November 2025) and down 25.2% over five years. Its highest weekly close since March 2016 was ₹804.65 on 2 January 2026. ### UPL share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹513.35 | +3.0% |
| 1 month ago · 1 Oct 2026 | ₹516.80 | +2.4% |
| 6 months ago · 8 May 2026 | ₹646.00 | −18.1% |
| 1 year ago · 7 Nov 2025 | ₹747.95 | −29.3% |
| 3 years ago · 3 Nov 2023 | ₹527.87 | +0.2% |
| 5 years ago · 4 Nov 2021 | ₹707.64 | −25.2% |
| 10 years ago · 4 Nov 2016 | ₹430.03 | +23.0% |
| Earliest and lowest weekly close in our records · 11 Mar 2016 | ₹280.42 | +88.6% |
| Highest weekly close since March 2016, also the 52-week high · 2 Jan 2026 | ₹804.65 | −34.3% |
| 52-week low (weekly close) · 9 Oct 2026 | ₹488.45 | +8.3% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 4 November 2026.)

## What is the latest news on UPL? 4 Nov 2026: UPL closed at ₹529.00, up 3.0% on the week and up 2.4% on the month. 3 Aug 2026: UPL held its results call for April to June 2026. Management guided: FY27 consolidated revenue growth 7-11% and operating profit growth 10-14%. ### Earlier

- 17 Jul 2026: ex-date for a dividend of ₹6 a share. - Results for April to June 2026: Revenue up 10.5% on a year earlier. ## What dividend does UPL pay? UPL paid ₹6 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 1.13% at the ₹529.00 close on 4 November 2026. The last was a dividend of ₹6 a share, ex-date 17 July 2026. ### UPL dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 17 Jul 2026 | ₹6 | Dividend |
| 11 Jul 2025 | ₹6 | Dividend |
| 12 Aug 2024 | ₹1 | Dividend |
| 3 Aug 2023 | ₹10 | Dividend |
| 27 Jul 2022 | ₹10 | Dividend |
| 14 Jul 2021 | ₹10 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. UPL Ltd paid out 26% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. One of those years shows a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 5 November 2026.)

## What did UPL management say on the latest results call? On the call for April to June 2026, held on 3 August 2026, UPL's management guided: FY27 consolidated revenue growth 7-11% and operating profit growth 10-14%. > “We are therefore guiding for full-year revenue growth of 7-11% and EBITDA growth of 10-14% for FY27.”
> Vikash Prasad, on the call for April to June 2026

### What management guided

- UPL Corp sustainable-solutions revenue approximately $700 million and new-product-launch revenue $150 million for the full year. - Global crop-protection demand flat to slightly up on a year earlier, with UPL Corp volume and market-share growth expected; pricing expected to remain firm. - India crop-protection full-year operating margin materially above last year; Q1 margin benefit to normalize as costs flow through. - Superform mix towards 55% Ag and 45% Super Specialty over next 3-4 years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/1388-03-Aug-2026.pdf). (From the call for April to June 2026, 3 August 2026.)

## What to watch in UPL's next results? When UPL reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: India crop-protection margins to normalize after Q1 timing effects - check whether full-year improvement remains materially above last year. - What to check (from the call)
- India crop-protection margins to normalize after Q1 timing effects - check whether full-year improvement remains materially above last year. - Superform specialty-chemicals growth to convert into operating profit despite planned spending - check margin delivery. - Debt refinancing assessment to progress before the next stated maturity - check liquidity execution. ## Which stock lists is UPL on? UPL is on one of our India lists: Small & mid cap stocks. [Small & mid cap stocks Size rank in India: 212](https://www.sectoralpha.in/small-cap-stocks-india)

## Is UPL profitable? UPL Ltd posted a net loss of ₹73.0 Cr in the Jun 2026 quarter. Full-year FY26 profit was ₹2,220 Cr. Over 10 years profit has grown 8.8% a year on average. That loss is 0.7% of the quarter's revenue. The same quarter a year earlier lost ₹176 Cr. 7 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹2,220 Cr (+170.7% on the year before). ## How much revenue does UPL make, and is it growing? UPL Ltd reported ₹10,181 Cr of revenue in the Jun 2026 quarter, +10.5% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 10 years it has grown 13.9% a year on average. The last full year, FY26, came in at ₹51,839 Cr. The last four reported quarters add to ₹52,804 Cr. FY26 revenue was ₹51,839 Cr, +11.2% on the year before. Recent pace: the last four quarters grew +12.3% on average, against 13.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.9%, against +10.6% a year over the last 8 quarters (stabilising). ## How much of every ₹100 of sales does UPL keep? UPL Ltd's operating margin was 13.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 10.0% and 22.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.7 percentage points on the year while gross margin changed +2.9 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is UPL's profit turning into cash? Over the last 3 years, 346% of UPL Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹7,855 Cr of operating cash against ₹2,220 Cr of profit. After ₹6,914 Cr of spending on assets, ₹941 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 346% of profit came in as cash: the cash cycle got 84 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does UPL's cash go? UPL Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 135 days in FY26, up from 51 days in FY21. It spent ₹12,526 Cr on assets over the last 3 years. Customers take 126 days to pay, and stock sits for 179 days on average. At FY26 sales of ₹51,839 Cr, each day of that cycle ties up about ₹142 Cr, so roughly ₹19,173 Cr is tied up in the business at any time. FY26: customers took 126 days to pay and stock sat for 179 days, about 5.9 months of sales sitting as stock, for a full cycle of 135 days, longer than FY21's 51. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 179 days. Customers pay about 126 days after that. Suppliers are paid at 169 days. Together that makes the 135-day cycle. Spending on assets: ₹12,526 Cr over the last 3 years, against ₹8,757 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹3,147 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is UPL's P/E ratio, and how does it compare with its own history? UPL Ltd's P/E is 22.6×, in the middle of its own history: higher than 53% of past readings. Its usual P/E (the middle reading) is 21.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹23.95. Why the multiple is where it is: over the past year earnings per share moved +114.5% while the price moved −29.3%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −5.7% a year; about −9.0% a year came from earnings growth and about +3.3 percentage points from the multiple (the market paying more); over 10 years the price moved +2.1% a year; about +7.0% a year came from earnings growth and about −4.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 113% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the UPL business getting better or worse? UPL Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does UPL earn on its capital? UPL Ltd earned a ROCE of 10% in FY26. That is up from a low of 3% in FY24. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 4.3% net margin and 0.56× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 4.3% net margin × 0.56× asset turnover × 2.68× leverage (assets divided by equity) ≈ 6.5% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 113% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does UPL have too much debt? UPL Ltd had ₹23,576 Cr of borrowings against ₹34,696 Cr of equity in FY26, so its debt is 0.68× its equity. Its operating profit is 3 times its interest bill. Over 5 years borrowings went from ₹24,519 Cr to ₹23,576 Cr. Over the last 3 of those years it spent ₹12,526 Cr on assets. The spending on assets is being paid for from cash, not new debt. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 113% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the UPL shareholding pattern? Foreign institutions raised their stake in UPL Ltd by 9.8 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 42.4% of the company. Domestic institutions moved −4.6 points over the same period, to 14.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +9.8 points over 8 quarters, to 42.4%; Domestic institutions: −4.6 points over 8 quarters, to 14.3%; Promoters: +0.0 points over 8 quarters, to 33.5%. Why the owners changed: foreign institutions moved +9.8 points and domestic institutions −4.6 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is UPL from balance-sheet trouble? For UPL Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does UPL rank in its industry? 41.5 out of 100, rank 21 of 25 in Pesticides/Agrochemicals, with 71% of the evidence available. UPL Ltd scores 41.5 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 21. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 16.6 + 7.8 + 7.9 + 9.2 = 41.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is UPL compared with? UPL ranks 21 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 41.5 out of 100. 1. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) SHARDACROP · basing · Most evidence points up · 100% evidence 71.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 17.3% · Profit 42.5% · Operating margin change 2 points · 100% evidence Capital efficiency 19.5/25 · ROCE 30.2% · Operating margin 16% · 100% evidence Valuation 19.2/20 · P/E 9.3× · PEG 0.3 · 100% evidence Relative strength 4.6/20 · Lead over its industry -14.3% · Lead over NIFTY 500 -22.1% · 1 year -23.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28.5 + 19.5 + 19.2 + 4.6 = 71.8 · What this means: Earnings are strong; relative strength in its sector is -14.3% and the one-year return is -23.1%. 2. [Titan Biotech Ltd](https://www.sectoralpha.in/stocks/titan-biotech-ltd) turning · Most evidence points up · 83% evidence 70.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.1/35 · Revenue 31.8% · Profit 38.7% · Operating margin change 2 points · 83% evidence Capital efficiency 20.2/25 · ROCE 22.8% · Operating margin 21% · 95% evidence Valuation 5.4/20 · P/E 51.8× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 38.3% · Lead over NIFTY 500 25.1% · 1 year 101.5% · 100% evidence · 4 of 12 weeks ahead Exact sum: 28.1 + 20.2 + 5.4 + 16.7 = 70.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Dharmaj Crop Guard Ltd](https://www.sectoralpha.in/stocks/dharmaj-crop-guard-ltd) DHARMAJ · losing its lead · Most evidence points up · 81% evidence 65.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 8.7% · Profit 13.2% · Operating margin change 1 points · 88% evidence Capital efficiency 16.5/25 · ROCE 16.8% · Operating margin 15% · 100% evidence Valuation 17.5/20 · P/E 14.3× · PEG 0.38 · 100% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 4.7% · 1 year -9.9% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.8 + 16.5 + 17.5 + 12.2 = 65 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) BAYERCROP · quiet · Evidence leans up · 81% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue -2.8% · Profit 23.8% · Operating margin change 2 points · 88% evidence Capital efficiency 19.7/25 · ROCE 29.1% · Operating margin 20% · 100% evidence Valuation 13.4/20 · P/E 20× · PEG 1.28 · 100% evidence Relative strength 8.6/20 · Lead over its industry n/a · Lead over NIFTY 500 -20.8% · 1 year -33.3% · 25% evidence · 0 of 12 weeks ahead Exact sum: 22.3 + 19.7 + 13.4 + 8.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Punjab Chemicals & Crop Protection Ltd](https://www.sectoralpha.in/stocks/punjab-chemicals-crop-protection-ltd) PUNJABCHEM · quiet · Evidence leans up · 81% evidence 63.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 8.2% · Profit 43.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.7/25 · ROCE 18.6% · Operating margin 12% · 100% evidence Valuation 15.9/20 · P/E 17.4× · PEG 0.33 · 100% evidence Relative strength 9.8/20 · Lead over its industry n/a · Lead over NIFTY 500 -9.4% · 1 year -36.4% · 25% evidence · 6 of 12 weeks ahead Exact sum: 24.3 + 13.7 + 15.9 + 9.8 = 63.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Advance Agrolife Ltd](https://www.sectoralpha.in/stocks/advance-agrolife-ltd) ADVANCE · breaking out · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.1/35 · Revenue 48.4% · Profit 81.5% · Operating margin change 1 points · 88% evidence Capital efficiency 14.0/25 · ROCE 19.6% · Operating margin 11% · 100% evidence Valuation 10.3/20 · P/E 16.3× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 10.6% · 1 year -8.6% · 25% evidence · 12 of 12 weeks ahead Exact sum: 22.1 + 14 + 10.3 + 12.4 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [India Pesticides Ltd](https://www.sectoralpha.in/stocks/india-pesticides-ltd) IPL · quiet · Evidence leans up · 81% evidence 57.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue 17% · Profit 10.1% · Operating margin change -2 points · 88% evidence Capital efficiency 13.9/25 · ROCE 16.6% · Operating margin 14% · 100% evidence Valuation 18.2/20 · P/E 12× · PEG 0.36 · 100% evidence Relative strength 8.2/20 · Lead over its industry n/a · Lead over NIFTY 500 -23% · 1 year -40.7% · 25% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 13.9 + 18.2 + 8.2 = 57.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) DHANUKA · turning · Evidence leans up · 100% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0% · Profit 0.7% · Operating margin change 0 points · 100% evidence Capital efficiency 19.7/25 · ROCE 25.9% · Operating margin 23% · 100% evidence Valuation 9.2/20 · P/E 14.4× · PEG 2.27 · 100% evidence Relative strength 17.4/20 · Lead over its industry 7.1% · Lead over NIFTY 500 -2.8% · 1 year -28.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 10.8 + 19.7 + 9.2 + 17.4 = 57.1 · What this means: Relative strength against the index is -2.8%, and revenue and profit growth are weak. 9. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) JUBLINGREA · quiet · Evidence leans up · 93% evidence 54.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 15.4% · Profit 21.9% · Operating margin change 3 points · 100% evidence Capital efficiency 13.4/25 · ROCE 11.4% · Operating margin 15% · 100% evidence Valuation 6.7/20 · P/E 24.7× · PEG 2.26 · 65% evidence Relative strength 8.4/20 · Lead over its industry -2.6% · Lead over NIFTY 500 -11.7% · 1 year -19.1% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 13.4 + 6.7 + 8.4 = 54.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Meghmani Organics Ltd](https://www.sectoralpha.in/stocks/meghmani-organics-ltd) MOL · breaking out · Evidence leans up · 64% evidence 51.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue -7.8% · Profit 100% · Operating margin change 7 points · 88% evidence Capital efficiency 9.3/25 · ROCE 6.7% · Operating margin 18% · 100% evidence Valuation 9.6/20 · P/E 20.8× · PEG n/a · 15% evidence Relative strength 11.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.5% · 1 year -35% · 25% evidence · 11 of 12 weeks ahead Exact sum: 22 + 9.3 + 9.6 + 11 = 51.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [GSP Crop Science Ltd](https://www.sectoralpha.in/stocks/gsp-crop-science-ltd) GSPCROP · quiet · Too little evidence to rank firmly · 59% evidence 51.0 out of 100 Growth Capital Valuation Relative
12. [Epigral Ltd](https://www.sectoralpha.in/stocks/epigral-ltd) EPIGRAL · quiet · Evidence leans down · 81% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [Rallis India Ltd](https://www.sectoralpha.in/stocks/rallis-india-ltd) RALLIS · quiet · Evidence leans down · 85% evidence 48.4 out of 100 Growth Capital Valuation Relative
14. [Bharat Rasayan Ltd](https://www.sectoralpha.in/stocks/bharat-rasayan-ltd) BHARATRAS · quiet · Evidence leans down · 96% evidence 45.3 out of 100 Growth Capital Valuation Relative
15. [Bhagiradha Chemicals & Industries Ltd](https://www.sectoralpha.in/stocks/bhagiradha-chemicals-industries-ltd) BHAGCHEM · quiet · Evidence leans down · 96% evidence 44.8 out of 100 Growth Capital Valuation Relative
16. [Shivalik Rasayan Ltd](https://www.sectoralpha.in/stocks/shivalik-rasayan-ltd) SHIVALIK · Evidence leans down · 63% evidence 43.9 out of 100 Growth Capital Valuation Relative
17. [Excel Industries Ltd](https://www.sectoralpha.in/stocks/excel-industries-ltd) EXCELINDUS · quiet · Evidence leans down · 64% evidence 42.7 out of 100 Growth Capital Valuation Relative
18. [NACL Industries Ltd](https://www.sectoralpha.in/stocks/nacl-industries-ltd) NACLIND · basing · Evidence leans down · 96% evidence 42.0 out of 100 Growth Capital Valuation Relative
19. [Best Agrolife Ltd](https://www.sectoralpha.in/stocks/best-agrolife-ltd) BESTAGRO · quiet · Evidence leans down · 90% evidence 41.9 out of 100 Growth Capital Valuation Relative
20. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) SUMICHEM · quiet · Evidence leans down · 85% evidence 41.8 out of 100 Growth Capital Valuation Relative
21. UPL Ltd this page UPL · basing · Evidence leans down · 71% evidence 41.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.6/35 · Revenue 12.9% · Profit 98.4% · Operating margin change -2 points · 62% evidence Capital efficiency 7.8/25 · ROCE 10.1% · Operating margin 13% · 76% evidence Valuation 7.9/20 · P/E 21.9× · PEG n/a · 50% evidence Relative strength 9.2/20 · Lead over its industry -7.6% · Lead over NIFTY 500 -16.1% · 1 year -28.7% · 100% evidence · 0 of 12 weeks ahead Exact sum: 16.6 + 7.8 + 7.9 + 9.2 = 41.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 22. [Insecticides India Ltd](https://www.sectoralpha.in/stocks/insecticides-india-ltd) INSECTICID · quiet · Evidence leans down · 96% evidence 40.5 out of 100 Growth Capital Valuation Relative
23. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) PIIND · quiet · Evidence leans down · 81% evidence 38.3 out of 100 Growth Capital Valuation Relative
24. [Astec Lifesciences Ltd](https://www.sectoralpha.in/stocks/astec-lifesciences-ltd) ASTEC · quiet · Most evidence points down · 71% evidence 32.7 out of 100 Growth Capital Valuation Relative
25. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) HERANBA · quiet · Most evidence points down · 76% evidence 29.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pesticides/Agrochemicals](https://www.sectoralpha.in/sectors/pesticides-agrochemicals), all 25 compared on one page. ## Which companies are close to UPL in size? UPL is the largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (scores of 30 October 2026). It is the largest. Just below it: P I Industries, Sumitomo Chemical India, Bayer CropScience, Jubilant Ingrevia, Sharda Cropchem and Dhanuka Agritech. ### Pesticides/Agrochemicals companies close in size

1. UPL Ltd ₹43,322 crore
2. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) ₹31,861 crore
3. [Sumitomo Chemical India Ltd](https://www.sectoralpha.in/stocks/sumitomo-chemical-india-ltd) ₹15,728 crore
4. [Bayer CropScience Ltd](https://www.sectoralpha.in/stocks/bayer-cropscience-ltd) ₹14,636 crore
5. [Jubilant Ingrevia Ltd](https://www.sectoralpha.in/stocks/jubilant-ingrevia-ltd) ₹8,894 crore
6. [Sharda Cropchem Ltd](https://www.sectoralpha.in/stocks/sharda-cropchem-ltd) ₹6,000 crore
7. [Dhanuka Agritech Ltd](https://www.sectoralpha.in/stocks/dhanuka-agritech-ltd) ₹4,369 crore

[All 25 Pesticides/Agrochemicals companies, largest first](https://www.sectoralpha.in/sectors/pesticides-agrochemicals#all-companies)

### Companies close in size in other industries

1. [Colgate-Palmolive (India) Ltd](https://www.sectoralpha.in/stocks/colgate-palmolive-indialtd) ₹43,423 crore · FMCG - Personal Care
2. [Fertilizers & Chemicals Travancore Ltd](https://www.sectoralpha.in/stocks/fertilizers-chemicals-travancore-ltd) ₹43,360 crore · Fertilisers
3. UPL Ltd ₹43,322 crore
4. [Piramal Finance Ltd](https://www.sectoralpha.in/stocks/piramal-finance-ltd) ₹42,996 crore · Conglomerate Backed NBFC
5. [Sterlite Technologies Ltd](https://www.sectoralpha.in/stocks/sterlite-technologies-ltd) ₹42,397 crore · Cables - Telecom

## What else do people ask about UPL? ### What is UPL's share price today? UPL Ltd's share price is ₹529.00, −29.3% over the past year. The whole company is worth ₹44,673 Cr on the market. In the last 52 weeks it traded between ₹488 to ₹805; today it is 13% of the way up from the low, 12.1% below its 200-day average (as of 4 November 2026). ### What were UPL's latest quarterly results? UPL Ltd reported revenue of ₹10,181 Cr and a net loss of ₹73.0 Cr for the Jun 2026 quarter. The operating margin was 13.0%, 2.0 percentage points lower than a year earlier (as of 4 November 2026). ### What is UPL's market cap? UPL Ltd's market capitalisation is ₹44,673 Cr at a share price of ₹529.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is UPL performing? UPL Ltd's share price has been falling for 33 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 6 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will UPL's share price go up? This page does not forecast UPL Ltd's share price. What it shows instead: the share price is ₹529.00, and it has been falling for 33 weeks. Its P/E of 22.6× is higher than 53% of its own last 11 years (as of 4 November 2026). ### Who owns UPL? Promoters own 33.5% of UPL Ltd, foreign institutions 42.4%, domestic institutions 14.3% and the public 9.8% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 9.8 percentage points over 8 quarters (as of 4 November 2026). ### Where is UPL in its business cycle? UPL Ltd's FY26 operating margin was 18.0%, against a 13-year range of 10.0% to 22.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 13.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the UPL story? The main question: yearly earnings per share moved +114.5% while the share price moved −29.3%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is UPL a stock worth studying right now? What the numbers show: UPL Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ### Is there a UPL share price forecast for 2026? What management itself guided: FY27 consolidated revenue growth 7-11% and operating profit growth 10-14%. ## Lists

- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india

This is research, not advice. We’re not SEBI-registered.